Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Buprelab
- Development stage
- Unknown
- Lead developer
- Labiana
- Modality
- Small Molecules
- Administration
- Intramuscular, Intravenous
01
Overview
Buprelab is a veterinary injectable formulation of buprenorphine hydrochloride, a semi-synthetic opioid derivative. It acts as a high-affinity partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Developed by Labiana, Buprelab is approved and marketed in several European countries for post-operative analgesia in dogs and cats, as well as for the potentiation of the sedative effects of centrally-acting agents in dogs.
- Brand names
- BuprelabBuprelab Vet
- Other names
- buprenorphinebuprenorphine hydrochloride
02
Targets
KOR (Kappa opioid receptor)MOR (Mu opioid receptor)
Beyond the preview
Go deeper on Buprelab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Buprelab.